Drug Type Monoclonal antibody |
Synonyms ZM012 |
Target |
Action inhibitors |
Mechanism Tumor-associated antigen inhibitors(Tumor-associated antigen inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Lymphoma | Preclinical | United States | 01 Oct 2025 |






